Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03172611 · ClinicalTrials.gov registry record · NA

A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles

A NA study, sponsored by Texas Woman's University.

Completed
Registry status
NA
Development phase
33
Enrollment target

NCT03172611: Completed NA study, sponsored by Texas Woman's University.

NCT03172611 is a NA study that has completed, run by Texas Woman's University. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03172611, a NA study, has completed, sponsored by Texas Woman's University.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target

Study Summary

This study evaluates the effects of consuming a defined, plant-based diet on lipoprotein(a) and other atherogenic particles associated with cardiovascular disease risk.

Primary Outcome

Serum Lp(a) (nmol/L) was documented at baseline and after 4-weeks

Interventions

  • OTHER Dietary Intervention

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2017-01-03
Est. Completion 2017-03-15
Phase NA
Texas Woman's University

51 total trials

What the finished NCT03172611 record still lists

NCT03172611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Dietary Intervention is the first listed.

NCT03172611 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03172611 about?

NCT03172611 is a clinical study titled "A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles". This study evaluates the effects of consuming a defined, plant-based diet on lipoprotein(a) and other atherogenic particles associated with cardiovascular disease risk.

What is the current status of trial NCT03172611?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2017-01-03. Estimated completion is 2017-03-15.

What interventions are being tested in trial NCT03172611?

The interventions under investigation include: Dietary Intervention (OTHER).

Who is sponsoring clinical trial NCT03172611?

This trial is sponsored by Texas Woman's University, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03172611's enrollment target sits among peer trials

33 1574th of 2000 higher than 423 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03172611, the US trial registry maintained by the National Library of Medicine. NCT03172611 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.